Topical roflumilast, 0.05%, is under consideration for treating mild to moderate atopic dermatitis in children aged 2-5 years ...

The global canine atopic dermatitis market is experiencing significant growth, projected to escalate from US$ 231.4 Mn in ...

The Canine Atopic Dermatitis Treatment Market is projected to grow from USD 1,182.60 million in 2024 to USD 1,620.50 million ...

Clinical phenotypes of atopic dermatitis can vary greatly based on skin color and can make atopic dermatitis difficult to diagnose.

This once-daily topical treatment is the latest phosphodiesterase-4 (PDE4) inhibitor designed for mild to moderate atopic ...

"We’re bringing impactful new science to this year’s AAD meeting, with new data on Nemluvio – our treatment for prurigo nodularis and atopic dermatitis – and the latest from our Dermatological ...

The goals of treating atopic dermatitis in all patients are to restore the function of the skin barrier and to prevent and control flares. 7 Most topical treatments for atopic dermatitis are ...

The FDA has granted Fast Track designation to rezpegaldesleukin for the treatment of moderate to severe atopic dermatitis.

The FDA has accepted the supplemental new drug application for Zoryve cream 0.05% to treat mild to moderate atopic dermatitis ...

Orismilast may be an effective and safe novel treatment option for adult patients with moderate to severe atopic dermatitis.

Patients with dupilumab prescriptions for their atopic dermatitis had lower risks for psychiatric and sleep disorders than those prescribed other treatments, according to a study published in Annals ...